Intest Res Search

CLOSE


Intest Res > Volume 9(3); 2011 > Article
Intestinal Research 2011;9(3):189-195.
DOI: https://doi.org/10.5217/ir.2011.9.3.189    Published online December 30, 2011.
Comparison of Infliximab and Infliximab/Azathioprine for Maintenance Therapy in Korean Patients with Luminal Crohn's Disease
Hyun Sun Won, Dong Il Park, Chang Uk Chon, Hyo Sun Seok, Tae Wan Kim, Woon Je Heo, Chang Kyun Lee, Chang Soo Eun2, Dong Soo Han2, Suck-Ho Lee3
1Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Kyung Hee University School of Medicine
2Seoul, Hanyang University College of Medicine
3Guri, Soonchunhyang University College of Medicine, Cheonan, Korea
한국인 크론병의 Infliximab 유지치료 시 Infliximab 단독 투여와 Infliximab과 Azathioprine 병합 투여 비교
원현선, 박동일, 전창욱, 석효선, 김태완, 허운제, 이창균, 은창수2, 한동수2, 이석호3
1성균관대학교 의과대학 강북삼성병원, 경희대학교 의과대학
2한양대학교 의과대학
3순천향대학교 의과대학 내과학교실
Abstract
Background/Aims
The benefits and risks of concomitant immunomodulators with infliximab maintenance therapy in patients with luminal Crohn's disease (CD) have not been adequately evaluated. We studied the influence of immunomodulator discontinuation in patients in remission with infliximab therapy through a restrospective case- control study. Methods: Medical records of 37 patients with luminal CD who received infliximab at four medical centers were retrospectively analyzed. We compared clinical and follow-up data of patients who were treated with infliximab alone with that of patients with combination therapy. Results: Among 37 patients, 31 (83.7%) were treated with infliximab plus azathioprine and six (16.2%) were treated with infliximab alone. Of the 31 patients receiving combination maintenance therapy, 26 (83.9%) were in complete remission after 12 months, as compared with five of six patients (83.3%) receiving infliximab alone. No significant difference was observed in remission rate between two groups (P=0.735). In total, 16.1% of patients in combination therapy and 16.7% in infliximab alone group reported side effects (P=1.000), but serious adverse events such as reactivation of tuberculosis were noted in only one patient in combination therapy group. Conclusions: Concomitant immunomodulators did not improve efficacy in patients with luminal CD who received scheduled infliximab maintenance. (Intest Res 2011;9:189-195)
Key Words: Crohn's Disease, Infliximab, Azathioprine
TOOLS
Share :
Facebook Twitter Linked In Google+ Line it
METRICS Graph View
  • 1 Crossref
  •   Scopus
  • 391 View
  • 2 Download
We recommend


ABOUT
ARTICLE CATEGORY

Browse all articles >

BROWSE ARTICLES
EDITORIAL POLICY
AUTHOR INFORMATION
Editorial Office
Room 305, Lotte Gold Rose II, 31 Seolleung-ro 86-gil, Gangnam-gu, Seoul 06193, Korea
Tel: +82-2-957-6145    Fax: +82-2-957-6146    E-mail: thekasid@irjournal.org                

Copyright © 2019 by Korean Association for the Study of Intestinal Diseases. All rights reserved.

Developed in M2community

Close layer
prev next